PMID: 37445623
The benefits are genuine, but they flow through the vasculature, the nervous system, and secondary mediators more than through the organs working cells, a distinction that matters when designing drugs meant to target these tissues
On these same online marketplaces, users rely on social media tutorials and influencers for advice on how to self-administer peptides, which are supplied as powders or injections in poorly labeled or unmarked vials
Not intended for human consumption, clinical diagnosis, or therapeutic application
Survodutide Timeline Boehringer Ingelheims SYNCHRONIZE program includes multiple Phase 3 trials: SYNCHRONIZE-1: Obesity without type 2 diabetes (726 participants, 76 weeks) SYNCHRONIZE-2: Obesity with type 2 diabetes (755 participants, 76 weeks) SYNCHRONIZE-CVOT: Cardiovascular outcomes (4,935 participants target) LIVERAGE trials: MASH-specific studies initiated October 2024 FDA Breakthrough Therapy designation for MASH may accelerate review for that indication specifically
Cost & Pricing Research peptide, compounded, and projected commercial costs
